FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy

FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy

Objectives To assess the efficacy and safety of golimumab (GLM) in Japanese patients (pts) with active RA despite MTX therapy. Methods GO-FORTH is a multicenter, randomized, double-blind, placebo (PBO)-controlled study in pts with active RA despite MTX. Pts were randomized to SC PBO, GLM50 mg, or GL...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.372
Hauptverfasser: Tanaka, Y., Harigai, M., Takeuchi, T., Yamanaka, H., Ishiguro, N., Yamamoto, K., Kanazawa, M., Murakami, Y., Yoshinari, T., Baker, D., Miyasaka, N., Koike, T.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives To assess the efficacy and safety of golimumab (GLM) in Japanese patients (pts) with active RA despite MTX therapy. Methods GO-FORTH is a multicenter, randomized, double-blind, placebo (PBO)-controlled study in pts with active RA despite MTX. Pts were randomized to SC PBO, GLM50 mg, or GLM100 mg q4 wks. All pts received MTX 6-8 mg orally/wk. Pts with
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2012-eular.2634